- CH₣232.94bn
- CH₣265.12bn
- $56.33bn
Novartis misses quarterly profit estimates on steep generic erosion (updated)
Novartis Q1 profit down on US generic erosion
Switzerland's Novartis misses Q1 sales, profit estimates on US generic competition; backs FY view
Swiss stocks - Factors to watch on April 28
Morning Bid Europe: BOJ's hawkish hold
Novartis receives European Commission approval for Rhapsido skin disease drug
Brief: Novartis Rhapsido wins EC approval as first oral targeted CSU treatment
Brief: Novartis AG - Receives Positive CHMP Opinion For Itvisma For Spinal Muscular Atrophy (SMA)
US investors crave predictability after Orban's overnight law changes
Table: Swiss trade surplus at CHF 3.18 bln in March
Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma
Swiss stocks - Factors to watch on April 15
Anthropic adds Novartis CEO Vas Narasimhan to its board
Brief: Novartis Announces Expansion Of Community Health Programs To Close Gaps In Heart Disease And Cancer Care
Factbox: Global pharma companies that have publicly announced Trump drug pricing agreements
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Focus: Drugmakers delay some European launches with a wary eye on Trump's pricing policies
Brief: Novartis Igan Data Slowed Kidney Function Decline By 49.3%
Deals of the day-Mergers and acquisitions